29083-17-8

Basic information

• Product Name: 1,2-BENZISOTHIAZOL-3(2H)-ONE, 5-METHOXY, 1,1-DIOXIDE
• Synonyms: 1,2-BENZISOTHIAZOL-3(2H)-ONE, 5-METHOXY, 1,1-DIOXIDE
• CAS NO: 29083-17-8
• Molecular Formula: C8H7NO4S
• Molecular Weight: 213.21
• Mol File: 29083-17-8.mol
• Article Data: 2

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1,2-BENZISOTHIAZOL-3(2H)-ONE, 5-METHOXY, 1,1-DIOXIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 1,2-BENZISOTHIAZOL-3(2H)-ONE, 5-METHOXY, 1,1-DIOXIDE(29083-17-8)
• EPA Substance Registry System: 1,2-BENZISOTHIAZOL-3(2H)-ONE, 5-METHOXY, 1,1-DIOXIDE(29083-17-8)

Safety Data

• Hazardous Substances Data: 29083-17-8(Hazardous Substances Data)

Usage

Structure

A derivative of benzisothiazolone with a methoxy group attached to the fifth carbon atom and a dioxide group connected to the first carbon atom.

Applications

Corrosion inhibitor
Biocide
Intermediate in the production of other chemicals
Water treatment chemicals
Preservative in detergents and personal care products

Potential medicinal uses

Antioxidant
Drug for treating neurodegenerative diseases

Upstream product

• 29632-82-4 5-bromo-1,1-dioxo-1,2-dihydro-1λ6-benzo[d]isothiazol-3-one 
• 100-84-5 1-methoxy-3-methyl-benzene 
• 108-39-4 3-methyl-phenol 
• 59554-30-2 5-methoxy-toluene-2-sulfonic acid 
• 7134-05-6 5-methyl-1-hydroxybenzene-4-sulfonic acid 
• 65397-56-0 2-chlorosulfonyl-5-methoxy-benzoic acid methyl ester 
• 29083-10-1 2-tert-butylsulfamoyl-5-methoxy-benzoic acid 
• 59554-42-6 4-methoxy-2-methylbenzenesulfonamide 
• 446054-08-6 5-methoxy-2-sulfo-benzoic acid 

Relevant articles and documents

Preparation method and medical application of benzisothiazole and benzothiophene

The invention discloses a preparation method and medical application of benzisothiazole and benzothiophene, and telates to the field of pharmaceutical chemistry. According to the invention, benzisothiazole and benzothiophene are the first type of HIF-2 agonists; compared with a compound M1001 found by the applicant in the earlier stage, the invention has better HIF-2 agonist activity, and has remarkable enhancement activity on expression of mRNA and protein of EPO, VGEF, Glut1, NDRG1 and the like at the downstream of HIF-2, so that the invention can be used for preparing drugs for treating and/or preventing chronic kidney diseases/chronic renal anemia, dyslipidemia and high cholesterol caused by abnormal expression of HIF-2; and the method has a good industrialization prospect.